The Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1) is essential for EBV-induced immortalization of human primary B cells, transforms rodent fibroblasts and induces the up-regulation of several B cell activation markers when transiently expressed in primary B cells. The biochemical function of LMP-1 is unclear and limited information is available on the involvement of different domains of the protein in B cell activation. The present study describes the characterization of LMP-1 N-and C-terminal deletion mutants in terms of their cell surface distribution and ability to induce activation markers in primary human B cells and in the type I Burkitt's lymphoma cell line DG75. The C-terminal deletion mutant was detected by immunofluorescenee via antibodies targeted against an eight amino acid FLAG epitope substituted for the entire predicted cytoplasmic C-terminal domain. Our findings show that N-terminal deletion mutants of LMP-1 are unable to attain their usual patched distribution on the plasma membrane but retain the ability to activate B cells. In contrast, the C-terminal deletion mutant shows the same patched cell surface distribution as wild-type LMP-1 but is unable to activate B cells. The patched distribution of LMP-1 in the plasma membrane is therefore not sufficient nor necessary for the induction of B cell activation and the results rule out patching as a direct mechanism in LMP-l-induced activation. This is the first study addressing the role of the LMP-1 C-terminal domain in lymphocytes and our results show that this domain is essential for B cell activation and therefore likely to be important for the early events of B cell immortalization by EBV.
Introduction
Epstein-Barr virus (EBV) immortalizes human primary B cells in vitro and the resulting lymphoblastoid cell lines (LCLs) express nine EBV-encoded proteins (reviewed in Sugden, 1989; Kieff & Liebowitz, 1990) , including latent membrane protein 1 (LMP-1) which is necessary for immortalization to take place (Kaye et al., 1993) . LMP-1 transforms rodent cell lines as assayed by tumorigenicity in nude mice and foci formation (Wang et al., 1985) , and LMP-1 is frequently expressed in EBV-associated malignancies. Thus, the LMP-1 protein is detected in more than 60% of all nasopharyngeal carcinomas (F~hraeus et al., 1988) , in Reed-Sternberg cells of Hodgkin's lymphomas (Herbst et al., 1991) and in some T cell leukaemias (Chen et al., 1993; Anagnostopoulos et al., 1992; Su et al., 1991) .
LMP-1 is a multiple transmembrane domain protein found in the plasma membrane and oriented in such a way that both the C and N termini are cytoplasmic (Liebowitz et al., 1986; Fennewald et al., 1984; Hennessy et al., 1984) . LMP-1 is proposed to have a short hydrophilic N terminus, approximately 25 amino acids long, that lacks a characteristic signal peptide. The N terminus is followed by six hydrophobic ~-helical transmembrane domains of approximately 20 amino acids, separated by reverse-turn loops consisting of eight to 10 amino acids. Finally, the bulk of the LMP-1 molecule consists of an approximately 200 amino acid long cytoplasmic C-terminal domain. This part of the molecule is rich in acidic residues and contains several potential phosphorylation sites, some of which have been shown to be functional in vivo (Moorthy & Thorley-Lawson, 1993b) . LMP-1 is distributed as discrete patches in the plasma membrane and associates with the cytoskeleton in lymphocytes and transfected fibroblasts (Liebowitz et al., 1987; Martin & Sugden, 1991) . The half-life of LMP-1 is rather short (2-5 h); the protein probably undergoes proteolysis at its C terminus (Baichwal & Sugden, 1987; Mann & Thorley-Lawson, 1987) .
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Besides transformation of rodent fibroblasts, LMP-1 expression induces many phenotypic changes in a variety of cell types. In particular, LMP-1 expression in type I Burkitt's lymphoma (BL) cell lines, which have several characteristics of resting B cells (Rowe et al., 1987a) , leads to an increase in cell size, up-regulation of activation cell surface markers such as ICAM-1, LFA-1, CD23, CD21 (the EBV receptor) and CD71 (transferrin receptor), induction of plasma membrane ruffling and villous projections (Wang et al., 1988) and induction of bcl-2 (Henderson et al., 1991; Martin et al., 1993; Rowe et al., 1994) . Induction of activation markers also follows expression of LMP-1 in human T or erythroleukaemic cell lines, as well as in human primary T cells and B cell chronic lymphocytic leukaemia cells (Peng & Lundgren, 1993) . Importantly, transient expression of LMP-1 in human primary B cells leads to induction of activation markers, cell size increase and DNA synthesis (Peng & Lundgren, 1992) .
The biochemical activity of LMP-1 remains unclear. Following efforts to pinpoint the domains of the LMP-1 protein which account for its biological activities, several mutational analyses have been published. The findings relevant to the present study may be summarized as follows: firstly, the cytoplasmic N-terminal domain is essential for the patched distribution of LMP-1 and its cytoskeletal association (Martin & Sugden, 1991 ; Liebowitz et al., 1992) , as well as for the induction of anchorage-independent growth in BALB/c 3T3 cells (Martin & Sugden, 1991) . However, this domain appears to be dispensable for the ability of LMP-1 to induce the activated phenotype in a type I BL cell line (Liebowitz et al., 1992) and it has recently been shown that deletions in this region do not inhibit B cell transformation (Izumi et al., 1994) . Secondly, deletions of the cytoplasmic C terminus greatly decrease or completely abolish the ability of LMP-1 to transform Rat-1 fibroblasts (Moorthy & Thorley-Lawson, 1993 a) but do not impair BALB/c 3T3 cell transformation (Martin & Sugden, 1991; . Importantly, Cterminal deletion mutants have not been studied in B cells, which are the natural host for EBV. The characterization of C terminal mutants is limited because the available LMP-1 antibodies are targeted against this region and so deletion mutants cannot be detected.
It is important to study LMP-1 activity in human primary B cells because the functions of LMP-1 probably evolved in association with this cell type. The use of transient expression of LMP-1 mutants in primary B cells is therefore a means to investigate LMP-l-induced events early infection, in a cell system that is as close to the in vivo situation as possible. This report describes the characterization of LMP-1 N-and C-terminal deletion mutants in terms of their cell surface distribution and ability to induce activation markers both in the type I BL line DG75 and in human primary B cells. The Cterminal deletion mutant was detected by immunofluorescence via antibodies targeted against an eight amino acid FLAG epitope substituted for the entire predicted cytoplasmic C-terminal domain. The data presented in this report show that the N terminus is essential for the patched distribution of LMP-1 on the plasma membrane but is not essential for B cell activation, while the C-terminal deletion mutant exhibits the same patched distribution as wild-type LMP-1 but is unable to activate B cells.
Methods
Cells. DG75 (Rowe et al., 1986 ) is an EBV-negative BL cell line and CB-M1-Ral-STO is a LCL (Ernberg et aL, 1989) . Spleen B cells were purified as follows: the cells from a fresh human spleen were forced through a steel mesh while constantly rinsing with PBS. The suspension was then layered on top of a one-fifth volume of Lymphoprep (Nycomed) and centrifuged to remove dead cells and erythrocytes. The lymphocyte layer was removed and washed three times with 3 volumes of PBS, divided into 2 x 108 cells per aliquot and frozen at -135 °C in a solution of 50 % fetal calf serum (FCS), 40 % RPMI-1640 medium and 10% DMSO. Prior to transfection, the cells were thawed and the B cells were positively selected using anti-CD19 immunomagnetic beads (Dynal) and pre-activated with 5 ng/ml of phorbol 12,13-dibutyrate to allow efficient transfection (Pilon et al., 1991; Peng & Lundgren, 1992) . All cells were maintained in growth medium, which consisted of RPMI-1640 supplemented with 10 % FCS and antibiotics, at 37 °C in a humidified atmosphere containing 5 % carbon dioxide.
Plasmids. Representations of the LMP-1 variants used in this study and their proposed orientation in the membrane are shown in Figs 1 and 2. Plasmid pCMVLMP1 supports expression of the wild-type LMP-1 protein from the human cytomegalovirus (HCMV) promoter (Peng & Lundgren, 1992) . In pCMVLMPA9 and pCMVLMPA15 a DNA segment (between the BamHl restriction site at position 790 and the XhoI site at position 856 in pCMVLMP1) was replaced by oligonucleotides encoding N-terminal deletions in the LMP-1 protein of amino acids 2-9 and 2-15, respectively. The same BamHI-XhoI segment was replaced by oligonucleotides encoding the FLAG amino acid sequence (MDYKDDDDK-) at the N-terminus of LMP-1 in pCMVLMPFN (Hoppet al., 1988) . This epitope is recognized by the mouse anti-FLAG M2 monoclonal antibody (IBI/Kodak).
The C-terminal deletion protein with the FLAG epitope at the C terminus was expressed from pCMVLMPACFC. This plasmid was produced by replacing a segment between the NcoI site at position 1521 and the XmaI site at position 2362 of pCMVLMP1 by a PCR product containing coding sequences for the FLAG epitope, followed by a stop codon and the 3' non-coding sequences. In the resulting protein the entire proposed cytosolic domain, starting at Gln-189, is exchanged for the eight residue FLAG epitope. Plasmid pCMVLMPAC was constructed similarly, but with a PCR product lacking the FLAG epitopeencoding sequences.
Plasmid pCMVLMPFC, which encodes an untruncated wild-type LMP-1 with the FLAG epitope added to the C terminus, was derived from pCMVLMPI: the DNA sequence between the NcoI site at position 2016 and an introduced KpnI site at position 2156 in the 3' non-coding region was exchanged for a PCR product encoding the FLAG residues after the C-terminal Asp-386 in LMP-1.
Plasmid pCMVLMPA (Peng & Lundgren, 1992 ) is a negative control plasmid, derived from pCMVLMP1, lacking a functional LMP-1 gene.
Plasmid pRCD2-2 (Peng & Lundgren, 1992 ) expresses a part of the rat CD2 (rCD2) and is used here as a co-transfeetion marker. The plasmid is a pBR322 derivative carrying the HCMV promoter and a eDNA (a kind gift from Dr A. F. Williams, Oxford, UK) encoding only the transmembrane and extracellular domains of rCD2. This recombinant is therefore unable to transduce signals (He et al., 1988; Ohno et al., 1991) .
Eleetroporation. This was performed under optimized conditions in 1 ml cuvettes with a 0.4 cm space between the electrodes (Bio-Rad). Each cuvette contained 107 cells in 500 ~tl (DG75 cells) or 350 tll (spleen B cells) of growth media. After the addition of DNA (which always included 10 pg of pRCD2-2 as a eo-transfection marker) the samples were gently mixed and kept at room temperature for 5 min. Electroporation was performed with the capacitor set at 960 laF and voltage at 300 V for DG75 cells or 340 V for spleen B cells. After electroporation the samples were kept at room temperature for 5 min before being diluted with 10 ml of culture medium. The number of viable cells was determined 24 h after eleetroporation using the trypan blue exclusion method and was 5-7 (_+ 1-2)× i0 o cells for DG75 celIs and 3-7 (+0"5) x 108 cells for spleen B cells; viability did not differ significantly between the transfeetions with the various constructs. Transfeetion efficiency was determined by flow cytometry where cells bearing the rCD2 antigen scored as positive; efficiency was 39.5 (-+ 8-3) % for DG75 cells and did not significantly vary between transfections with the various constructs. For B cells, transfection efficiency was 6.3 (_+1.2) % when transfection took place in the presence of the pCMVLMPACFC construct and 13.0 (_+2.5) % when using the other constructs.
Western blotting. Proteins (30 lag) from the total cell extracts of 107 transfected DG75 cells, prepared 18 h after transfection with 10 lag of the indicated plasmids, were separated by SDS PAGE according to the method of Laemmli (1970) and blotted onto nitrocellulose filters (Schleicher & Sehuell) according to the method of Towbin et al. (1979) . Excess protein-binding sites were blocked by incubating the filters overnight in TBS supplemented with 0"05 % Tween 20 and 5 % dried skimmed milk. To detect LMP-1 the filters were incubated for 2 h at room temperature with an appropriate dilution of the anti-LMP-1 monoclonal antibody S-12 (Mann et al., 1985) . The protein-antibody complexes were reacted with horseradish peroxidase-conjugated sheep anti-mouse secondary antibody and visualized using the ECL detection kit (Amersham) according to the manufacturer's instructions.
Immunofluorescence. At 48 h after transfection, the live cells were separated by Lymphoprep and cell smears were prepared. These were air-dried, fixed in acetone methanol (1 : 1) at -20 °C for 5 min and airdried at room temperature. The samples were pre-bloeked for 15 min in PBS containing 10% normal goat serum and 10% normal human serum (PBS/ngs/nhs) and incubated for 2 h at 37 °C in the presence of the CS1.4 pool of anti-LMP-1 monoclonal antibodies (Rowe et al., 1987b) diluted 1:5 in PBS/ngs/nhs, or in the presence of 10 lag/ml of the anti-FLAG M2 antibody (Kodak/IBI) diluted in PBS/ngs/nhs. They were then washed extensively in PBS before being incubated for 1 h at 37 °C in a 1:20 dilution of FITC-conjugated goat anti-mouse IgG1 secondary antibodies (Southern Biotechnology) in PBS/ngs/nhs. After washing in PBS, the nuclei were counterstained with propidium iodide and washed in PBS. The samples were analysed by epiftuorescence or using a Multiprobe 2001 confocal microscope (Molecular Dynamics). Micrographs shown in the figures are 'lookthrough' projections generated from 30-40 scanned sections with voxel sizes of 0.07 lam (width), 0.07 lam (length) and 0.3 lam (depth). These were acquired with amplifiers set to exploit and be within the dynamic range of the detectors.
Flow eytometry. Live-cell fluorescence was achieved using saturating amounts of FITC-conjugated anti-CD7i, anti-ICAM-1, an isotypematched control antibody (all purchased from Immunotech) and saturating amounts of biotinylated anti-rCD2 antibodies. This was followed by the addition of streptavidin-phycoerythrin to specifically label transfected cells. Prior to analysis, propidium iodide was added to a final concentration of 10 lag/ml. Binding was quantified using a flow cytometer (FACScan; Becton Dickinson) gated for side and forward light scatter as well as for propidium iodide-emitted fluorescence to monitor only live cells, and gated for phycoerythrin-emitted fluorescence to monitor only rCD2-positive cells (i.e. successfully transfected cells). For each sample at least 3000 live rCD2-positive cells were counted.
Results

Distribution of the LMP-1 mutants in transfected DG75 cells
In order to assess the importance of the N-and Cterminal domains for LMP-1 activity in B cells, we have generated various expression constructs that encode Nand C-terminal alterations in the LMP-1 protein in such a way that no parts of the proposed transmembrane helices were deleted. Furthermore, since available antibodies to LMP-I are directed against the cytoplasmic Cterminal domain, we chose to add a FLAG epitope to LMP-1 so that deletion mutants lacking the C terminus could be detected using an anti-FLAG antibody. Figs 1 and 2 show schematic illustrations of the putative secondary structures of LMP-1 and the mutants used in this study, as well as the terminology used for the constructs. At 48 h after transfection of DG75 cells with each construct, the cells were stained using the CS1-4 pool of monoclonal antibodies which recognize the cytoplasmic C-terminal domain of LMP-1, or an anti-FLAG antibody which detects the FLAG epitope of the protein expressed from pCMVLMPACFC. Both wildtype LMP-1 and the protein from pLMPACFC exhibited a characteristic patched plasma membrane distribution (Figs 1 and 2) . In contrast, mutants with nine or 15 amino acids deleted from the N terminus, as well as LMP-1 with the FLAG epitope added to the N terminus, exhibited diffuse cell surface staining (Figs 1 and 2) . Of several thousand cells staining positive for each of these three constructs, none exhibited patched cell-surface distribution. Thus, the N terminus is essential for the patched distribution of LMP-1.
The protein expressed from a positive control construct, pCMVLMPFC, in which the FLAG epitope was added to the C terminus of the full-length LMP-1, could be stained with either the anti-FLAG antibody (Fig. 2) or the CS1-4 pool of monoclonal antibodies (data not shown). It exhibited staining identical to the wild-type LMP-1 protein expressed from the pCMVLMP1 construct. This indicates that the FLAG epitope does not interfere with LMP-1 distribution. None of the LMP-1 variants tested in this study showed cytoplasmic staining. Protein from pLMPFN could not be detected by immunofluorescence using the anti-FLAG antibody. This was possibly because the epitope was not in the appropriate conformation, was shielded by interactions with other structures or, most likely, because of decreased protein stability leading to proteolysis of the N terminus. In support of the latter alternative, the protein expressed from construct pLMPFN (designated LMPFN) could not be detected by Western blots using the anti-FLAG antibody even though this antibody worked well for Western blot detection of the LMPFC and LMPACFC proteins (data not shown).
Western blotting of the LMP-1 proteins using the S-12 monoclonal antibody (Mann et al., 1985) was performed to obtain a rough estimate of the expression levels of the LMP-1 proteins (Fig. 3) . It is clear that the amount of full-length LMPFN is reduced compared to the expression levels for the other LMP-1 variants, strongly suggesting that the FLAG epitope at the N terminus destabilizes the protein. It was surprising to note the slower migration rate of LMPA9 compared to wild-type LMP-1. We have no obvious explanation for this, but it might be a consequence of conformational changes in the protein. DNA sequencing of the region coding for the N terminus of the protein showed the expected sequence (data not shown). Finally, as expected, no staining could be observed using either antibody CS1.4 (Fig. 2) or the anti-FLAG antibody (data not shown) in cells transfected with the control plasmid pCMVLMPAC. This plasmid differs from pCMVLMPACFC only in that it does not encode the F L A G epitope.
Effect of LMP-1 N-terminal deletions on ICAM-1 induction in DG75 cells
As a functional assay for biological activity in B cells, the ability of the various constructs to induce ICAM-1 in expressed high levels of rCD2 (compare pCMVLMPA9 and pCMVLMP1 transfectants in Fig. 1 ). Assuming that rCD2 expression levels correlate with LMP-1 expression levels (in agreement with model studies using CD2 and CD8 expression plasmids), this suggests that only those cells which express high levels of this LMP-1 variant could induce ICAM-1 up-regulation and thus LMPA9 is less active than wild-type LMP-1. However, when 15 amino acids were deleted from the N terminus of LMP-1, full wild-type activity was recovered (compare pCMVLMPA15 and pCMVLMP1 in Fig. 1 ). These results are compatible with a model where the N terminus of LMP-1 acts as an inhibitory domain in the LMPA9 variant. None of the tested constructs affected the binding of a control antibody, isotype-matched with the anti-ICAM-1 antibody (Fig. 1) .
31--21-5 -- transfected DG75 cells was studied 48 h after transfection. A rCD2 expression plasmid, pCMVRCD2-2, was used as a co-transfection marker to allow specific dualcolour flow cytometry analysis of viable and successfully transfected rCD2-positive cells, as previously described (Pilon et al., 1991 ; Peng & Lundgren, 1992 . The data on ICAM-1 induction by the various constructs are summarized in Table 1 and representative flow cytometry data are presented in Figs 1 and 2. Fig. 1 shows that wildtype LMP-1 induces up-regulation of ICAM-1 cell surface expression in DG75 cells (compare the pCMVLMP1 with the pCMVLMPA transfectants) and that ICAM-1 is induced in an apparently dose-dependent manner, as judging from the correlation between rCD2 and ICAM-1 intensity. The strongest ICAM-1 staining cells among the pCMVLMP1 transfectants (in which 43.2 % of the cells scored positive; Table 1) show almost 10-fold more staining than the control transfectants (Fig.  1) . Deletion of nine amino acids from the N terminus of LMP-1 resulted in reduced LMP-1 activity: some ICAM-1 up-regulation was observed but only in the cells which
Effects of a LMP-1 C-terminal deletion on ICAM-1 induction in DG75
In preparation for the analysis of a C-terminal deletion mutant that would be detected via the FLAG epitope, we investigated the effect of adding the FLAG epitope at either the C (in LMPFC) or N terminus (in LMPFN) on the ability of LMP-1 to cause ICAM-1 up-regulation. The LMPFC protein exhibited activity identical to wildtype LMP-I (compare pCMVLMPFC in Fig. 2 with pCMVLMP1 in Fig. 1 ). This result suggests that the end of the C terminus need not be of wild-type sequence for LMP-1 to exhibit full activity. In contrast, addition of the FLAG epitope to the N terminus reduced the activity of LMP-1 in a manner similar to the LMPA9 mutation (compare pCMVLMPFN in Fig. 2 with pCMVLMPA9 in Fig. 1 ). Because the presence of the FLAG epitope at the C terminus of the full-length LMP-1 protein interfered with neither localization nor activity, we chose to make a mutant protein where the entire cytoplasmic C terminus was substituted by the FLAG sequence. This mutant protein, LMPACFC, was completely unable to cause ICAM-1 up-regulation, even though it exhibited wild-type cell surface distribution (Fig. 2) . Transfection of up to 30 ~tg of the pCMVLMPACFC plasmid, instead of the usual 10 ~tg, could not induce any ICAM-1 upregulation, further confirming the inertia of this protein.
To exclude the possibility that the presence of the FLAG epitope in the LMPACFC protein was responsible for the lack of activity, the LMPAC protein was also tested for its ability to induce ICAM-1 up-regulation. This protein, like LMPACFC, was devoid of activity (Fig. 2) . None of the tested constructs affected the binding of a control antibody, isotype-matched with the anti-ICAM-1 antibody (Fig. 2) . 37.9 (4.1) 42.4 (6.6) 28.6 (1.3) 36.1 (4.0) pCMVLMPFC 37.7 (2.6) ND ND ND pCMVLMPFN 24"6 (2"7) 11"3 (2"0) 11"5 (1"6) 26"5 (2"4) pCMVLMPACFC 9"4 (1"9) 9"4 (1"7) 9"5 (0"3) 18"2 (1"9) pCMVLMPAC 7"5 (0"8) ND ND ND * Each value is the percentage of rCD2-positive cells that stained more strongly than the threshold level (see Fig. 1) , and is the average of three or more independent experiments. t FSC, light forward scattering count (a measure of cell size). The values given are the percentage of rCD2-positive cells above a threshold FSC value in flow cytometry.
:~ The SD are given in parentheses. ND, Not determined. 
Distribution of the LMP-1 mutants in transfected spleen B cells
To investigate whether the results obtained in DG75 cells applied also to primary B cells, the different mutants were tested for cell surface distribution and activity in human spleen B cells. Fig. 4 shows a representative field of spleen B cells transfected with the pCMVLMPA15 and stained with the CS1-4 antibody 24 h after transfection. This provides a visual evaluation of transfection efficiency and demonstrates the wide heterogeneity in expression levels among the transfected cells, which is in accordance with the variable rCD2 expression levels detected by flow cytometry. 
Induction of lCAM-1, CD71 and cell size increase in spleen B cells
The activity of the various constructs was evaluated by monitoring the surface expression levels of ICAM-1 and CD71, as well as cell size, in spleen B cells 48 h after transfection, essentially as done with DG75 cells ( Fig. 5 ; Finally, LMPACFC had no effect on ICAM-1 and CD71 expression. However, in contrast to the other LMP-1 mutants, LMPACFC caused a significant reduction of cell size in the transfected rCD2-positive cells and the cells expressing LMPACFC also showed reduced levels of the co-transfected rCD2 marker (see Methods). These effects of LMPACFC are unlikely to be caused by the presence of the FLAG epitope since both LMPFN and LMPFC, which also contain the FLAG epitope, did not affect rCD2 expression or cause a reduction in cell size. Furthermore, transfection of pCMVLMPAC, which differs from LMPACFC only in Hacking the FLAG epitope, gave results identical to pCMVLMPACFC in DG75 cells (Fig. 2) .
Discussion
The work presented here focuses on the requirements for the cytoplasmic N-and C-terminal domains of LMP-1 for the activation of primary B cells and the BL cell line DG75. Two main points are apparent from the combined results of the immunofluorescence microscopy and the B cell activation assay on the deletion mutants. Firstly, and this is the first report addressing this issue, the cytoplasmic C terminus is essential for B cell activation but is not involved in the patched distribution of the LMP-1 protein in the plasma membrane of B lymphocytes. This conclusion rests on the observation that LMP-1 mutants lacking this domain still show the patched distribution but are unable to activate B cells. Secondly, the cytoplasmic N terminus is essential for the patched distribution of LMP-1 in the plasma membrane of B lymphocytes, but is not essential for induction of B cell activation. Thus, patched distribution and ability to activate B cells are not coupled. The finding that the N terminus is dispensable for the up-regulation of B cell activation markers is in agreement with published data based on LMP-l-expressing B JAB stable clones (Liebowitz et al., 1992) and recombinant EBV with deletions in the N terminus of LMP-1 (Izumi et al., 1994) . It is interesting to note that the N-terminal domain is essential for mouse fibroblast transformation (Hammerschmidt et al., 1989; Martin & Sugden, 1991) . This indicates that transformation of rodent fibroblasts is not a phenomenon equivalent to that of B cell activation; it is possible that LMP-1 has two or more activities and that fibroblast transformation requires LMP-1 structures and functions that differ from those needed in B cell activation. Furthermore, patching and/or the cytoskeletal association of LMP-1 in EBVinfected cells might still be of importance to obtain high local concentrations of the protein and/or for targeting it to interacting molecules. The use of the strong HCMV promoter in the transfection experiments might result in sufficient LMP-1 expression to reach this concentration with the N-terminal deletion mutants, even without patching. However, transfection of pCMVLMPACFC with 30 ~g of DNA instead of the standard amount of 10 lag did not result in any activation (data not shown) showing that the function of the deleted C terminus could not be restored by over-expression of the protein.
In the B cell activation assays, it was surprising that the LMP-1 mutant lacking 15 amino acids from the N terminus (LMPA15) activated B cells more efficiently than the mutant lacking only nine of these amino acids (LMPA9) or the mutant with an added N-terminal FLAG epitope (LMPFN). This could be explained by differences in the degradation rates (probably true for LMPFN; see Fig. 3 ) or by unfavourable interactions between the remaining or modified N-termini of LMPA9 and LMPFN and other domains of LMP-1 or of other molecules, possibly indicating a regulatory role for this domain.
In summary, the results obtained in this work show that the cytoplasmic C-terminal domain, but not the Nterminal domain, is essential for the ability of LMP-1 to induce B cell activation. The patched distribution of LMP-1 in the plasma membrane is therefore not sufficient or necessary for the induction of B cell activation and the results rule out patching as a direct mechanism in LMP-l-induced activation. It seems likely that the C-terminal intracellular domain of LMP-1 is involved in molecular interactions that are important for the early events of B cell immortalization by EBV.
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antibody, an anti-ICAM-1 antibody or an anti-CD71 antibody (horizontal axes); the scales are logarithmic and the vertical dashed lines indicate the threshold above which lies 10 % of the cells that were transfected with the pCMVLMPA control construct. The right-hand graph shows the FSC (see Table 1 ) of rCD2-positive cells; the scale for the FSC axis is linear while that for rCD2 is logarithmic. The vertical lines indicate the threshold above which lies 25 % of the cells that were transfected with the pCMVLMPA control construct.
